bioAffinity Technologies, Inc.
BIAF
$-0.05
Change (1 day)
$3.62
Year High
$1.15
Year Low
Categories
bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat cancer at the cellular level. The company was founded in 2014 and is based in San Antonio, Texas.
Earnings for bioAffinity Technologies, Inc. (BIAF)
Earnings in 2023 (TTM): $-7,916,018
According to bioAffinity Technologies, Inc.'s latest financial reports the company's current earnings (TTM) are $-7,916,018. The earnings displayed on this page is the company's Pretax Income.
Earnings history of bioAffinity Technologies, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-7,916,018 | $-7,937,011 |
| 2022 | $-8,151,654 | $-8,154,113 |
| 2021 | $-6,324,463 | $-6,326,413 |
| 2020 | $-7,265,987 | $-7,268,737 |
| 2019 | $-3,304,299 | $-3,307,499 |